未登录

Z

Zegui Tu

Sichuan University

H指数:7

被引数:101

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The long-term spatiotemporal trends in lung cancer burden and its risk factors at global, regional, and national levels, 1992-2021: The Global Burden of Disease Study 2021

CANCER COMMUNICATIONS

IF24.9

2024-10-180

OAAI

CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer

TRANSLATIONAL LUNG CANCER RESEARCH

IF3.5

2024-05-012

OAAI

An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor

在线临床模型和风险分层系统预测PD-(L)1抑制剂治疗的晚期非小细胞肺癌患者的无进展生存期

IF3.6

2023-10-010

OAAI

Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review

MEK抑制剂曲美替尼单药治疗原发性SDN1-BRAF融合肺腺癌1例并文献复习

FRONTIERS IN ONCOLOGY

IF3.3

2022-08-198

OAAI

Expression of Microtubule-Associated Proteins in Relation to Prognosis and Efficacy of Immunotherapy in Non-Small Cell Lung Cancer

FRONTIERS IN ONCOLOGY

IF3.3

2021-10-0111

OAAI